EMIAT Amiodarone Trial

Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction EMIAT. European myocardial infarct amiodarone trial investigators. Lancet. Mar 8 1997 349(9053) 667-674. [Pg.47]

In the European Myocardial Infarction Arrhythmia Trial (EMIAT) amiodarone reduced the risk of dysrhythmic deaths from 8.5 to 4.1% compared with placebo (40). [Pg.151]

Boutitie F, Boissel JP, ConnoUy SJ, Camm AJ, Cairns JA, Juhan DG, Gent M, Janse MJ, Dorian P, Frangin G. Amiodarone interaction with beta-blockers analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. Circulation 1999 99(17) 2268-75. [Pg.172]

EMIAT (European Myocardial Infarction Amiodarone Trial), CAMIAT (Canadian Amiodarone/Arrhythmia Myocardial Infarction Trial), and BASIS (Basel Antiarrhythmic Study of Infarct Survival) evaluated the use of anpiric amiodarone after myocardial infarction (122,123,133). These studies did not show that amiodarone had a survival advantage however, a small but statistically significant reduction of sudden death (CAMIAT) and arrhythmic events (EMIAT) was observed. [Pg.503]

Big Chemical Encyclopedia